Endonovo Therapeutics, Inc. (OTCQB: ENDV) Marke
Post# of 416
(Total Views: 626)
Posted On: 02/20/2018 4:37:33 PM
Endonovo Therapeutics, Inc. (OTCQB: ENDV)
Market Cap: $11.6M, current share price: $.038
With the start of commercial sales of its non-invasive medical device, SofPulse(TM), for the palliative treatment of pain and post-surgical edema last month and an announced senior secured redeemable Series C Preferred Stock offering, Endonovo Therapeutics, Inc. (ENDV), a commercial stage developer of non-invasive Electroceuticals, has all the pieces in place for a successful launch of its cutting-edge therapy into the pain relief therapeutics market expected to reach $83 billion by 2024, according to Transparency Market Research. Endonovo's therapy works by treating the underlying cause of the pain itself: inflammation. Additionally, unlike other medical device companies that obtain FDA Clearance, Endonovo has reimbursement from Medicare for the treatment of chronic wounds, which places it advantageously to actually generate revenue from its products. Other companies with similar technologies have= failed to achieve the same clinical results as Endonovo's SofPulse(TM) in clinical trials for reducing pain following breast augmentation surgery. With positive clinical data in the treatment of ischemic cardiomyopathy in patients with failed medical therapy and revascularization options, ENDV is severely undervalued compared to its competitors, which are worth $250 to $320 million in market cap despite having smaller clinical pipelines with less than stellar clinical data and not having commercial stage products.
Market Cap: $11.6M, current share price: $.038
With the start of commercial sales of its non-invasive medical device, SofPulse(TM), for the palliative treatment of pain and post-surgical edema last month and an announced senior secured redeemable Series C Preferred Stock offering, Endonovo Therapeutics, Inc. (ENDV), a commercial stage developer of non-invasive Electroceuticals, has all the pieces in place for a successful launch of its cutting-edge therapy into the pain relief therapeutics market expected to reach $83 billion by 2024, according to Transparency Market Research. Endonovo's therapy works by treating the underlying cause of the pain itself: inflammation. Additionally, unlike other medical device companies that obtain FDA Clearance, Endonovo has reimbursement from Medicare for the treatment of chronic wounds, which places it advantageously to actually generate revenue from its products. Other companies with similar technologies have= failed to achieve the same clinical results as Endonovo's SofPulse(TM) in clinical trials for reducing pain following breast augmentation surgery. With positive clinical data in the treatment of ischemic cardiomyopathy in patients with failed medical therapy and revascularization options, ENDV is severely undervalued compared to its competitors, which are worth $250 to $320 million in market cap despite having smaller clinical pipelines with less than stellar clinical data and not having commercial stage products.
(0)
(0)Endonovo Therapeutics, Inc. (ENDV) Stock Research Links
WORDS TO LIVE BY:
Never argue with stupid people, they will drag you down to their level and then beat you with experience.
Get .... PrivacyLok https://cyberidguard.com/
Try SafeVchat: https://cyberidguard.com/
My comments are only my opinion and are not to be used for investment advice.
Please conduct your own due diligence before choosing to buy or sell any stock.
Never argue with stupid people, they will drag you down to their level and then beat you with experience.
Get .... PrivacyLok https://cyberidguard.com/
Try SafeVchat: https://cyberidguard.com/
My comments are only my opinion and are not to be used for investment advice.
Please conduct your own due diligence before choosing to buy or sell any stock.